Howe & Rusling’s Aurinia Pharmaceuticals AUPH Stock Holding History

Howe & Rusling’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-563	Closed	-$8K	–	800
2020 Q1	$8K	Sell	563 -39	-6%	-$688	﹤0.01%	445
2019 Q4	$12K	Hold	602	–	–	﹤0.01%	446
2019 Q3	$3K	Hold	602	–	–	﹤0.01%	613
2019 Q2	$4K	Sell	602 -31	-5%	-$198	﹤0.01%	555
2019 Q1	$4K	Sell	633 -33	-5%	-$219	﹤0.01%	558
2018 Q4	$5K	Buy	666 +279	+72%	+$1.61K	﹤0.01%	534
2018 Q3	$3K	Hold	387	–	–	﹤0.01%	659
2018 Q2	$2K	Hold	387	–	–	﹤0.01%	656
2018 Q1	$2K	Sell	387 -67	-15%	-$358	﹤0.01%	758
2017 Q4	$2K	Hold	454	–	–	﹤0.01%	697
2017 Q3	$3K	Hold	454	–	–	﹤0.01%	649
2017 Q2	$3K	Buy	454 +150	+49%	+$1.01K	﹤0.01%	699
2017 Q1	$2K	Buy	+304	New	+$1.4K	﹤0.01%	819

Other funds holding AUPH

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Howe & Rusling's AUPH Position: Q2 2020 in Review

Howe & Rusling sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2020, closing a stake of 563 shares — an estimated $8K sold.

Howe & Rusling first reported a position in AUPH in Q1 2017 and held it in 13 quarters. The position peaked at $12K in Q4 2019. 132 funds tracked by Wall St. Rank hold AUPH as of Q2 2020.

Howe & Rusling reported no remaining Aurinia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Howe & Rusling sold 563 Aurinia Pharmaceuticals shares in Q2 2020, an estimated $8K.
Howe & Rusling first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 13 quarters.
Howe & Rusling's Aurinia Pharmaceuticals position peaked at $12K in Q4 2019.
132 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2020.

Based on Howe & Rusling's 13F filing for Q2 2020, filed 15 Jul 2020.